92 related articles for article (PubMed ID: 1409866)
1. Haloperidol and reduced haloperidol serum levels: correlation with psychopathology in acute schizophrenia.
Stevens A; Mahal A; Gaertner HJ
Pharmacopsychiatry; 1992 Sep; 25(5):218-23. PubMed ID: 1409866
[TBL] [Abstract][Full Text] [Related]
2. Haloperidol and lorazepam combined: clinical effects and drug plasma levels in the treatment of acute schizophrenic psychosis.
Stevens A; Stevens I; Mahal A; Gaertner HJ
Pharmacopsychiatry; 1992 Nov; 25(6):273-7. PubMed ID: 1494594
[TBL] [Abstract][Full Text] [Related]
3. Haloperidol: therapeutic window in schizophrenia.
Palao DJ; Arauxo A; Brunet M; Bernardo M; Haro JM; Ferrer J; Gonzalez-Monclus E
J Clin Psychopharmacol; 1994 Oct; 14(5):303-10. PubMed ID: 7806684
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic window of serum haloperidol concentration in acute schizophrenia and schizoaffective disorder.
Ulrich S; Neuhof S; Braun V; Meyer FP
Pharmacopsychiatry; 1998 Sep; 31(5):163-9. PubMed ID: 9832347
[TBL] [Abstract][Full Text] [Related]
5. Reduced haloperidol/haloperidol ratios after oral haloperidol and decanoate administration in schizophrenics.
Chang WH; Lin SK; Juang DJ; Chen LC; Yang CH; Hu WH; Chien CP; Lam YF; Jann MW
Prog Neuropsychopharmacol Biol Psychiatry; 1993 Jan; 17(1):105-12. PubMed ID: 8416597
[TBL] [Abstract][Full Text] [Related]
6. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M
Encephale; 1995; 21(6):417-24. PubMed ID: 8674466
[TBL] [Abstract][Full Text] [Related]
7. Serum haloperidol and neuroleptic receptor levels in chronic psychosis.
Cannon DJ; McMillan DE; Newton JE; Fody EP; Metzer WS; Claybrook M; Couch L; Paige SR
Ann Clin Lab Sci; 1988; 18(5):378-83. PubMed ID: 3178137
[TBL] [Abstract][Full Text] [Related]
8. Serum prolactin as a correlate of clinical response to haloperidol.
Van Putten T; Marder SR; Mintz J
J Clin Psychopharmacol; 1991 Dec; 11(6):357-61. PubMed ID: 1770154
[TBL] [Abstract][Full Text] [Related]
9. Haloperidol blood levels and effects in schizophrenia and schizoaffective disorder: a progress report.
Volavka J; Cooper TB; Meisner M; Bitter I; Czobor P; Jaeger J
Psychopharmacol Bull; 1990; 26(1):13-7. PubMed ID: 2371368
[TBL] [Abstract][Full Text] [Related]
10. Adverse effects of risperidone and haloperidol treatment in schizophrenia.
Yen YC; Lung FW; Chong MY
Prog Neuropsychopharmacol Biol Psychiatry; 2004 Mar; 28(2):285-90. PubMed ID: 14751424
[TBL] [Abstract][Full Text] [Related]
11. Haloperidol decanoate in schizophreniform disorders. Clinical and neuroendocrine aspects.
Meco G; Casacchia M; Attenni M; Iafrate A; Castellana F; Ecari U
Acta Psychiatr Belg; 1983; 83(1):57-68. PubMed ID: 6613612
[TBL] [Abstract][Full Text] [Related]
12. Effects of repeated drug holidays on serum haloperidol concentrations, psychiatric symptoms, and movement disorders in schizophrenic patients.
Newton JE; Cannon DJ; Couch L; Fody EP; McMillan DE; Metzer WS; Paige SR; Reid GM; Summers BN
J Clin Psychiatry; 1989 Apr; 50(4):132-5. PubMed ID: 2925601
[TBL] [Abstract][Full Text] [Related]
13. Relationship of serum haloperidol levels to clinical response in schizophrenic patients.
Magliozzi JR; Hollister LE; Arnold KV; Earle GM
Am J Psychiatry; 1981 Mar; 138(3):365-7. PubMed ID: 7468835
[TBL] [Abstract][Full Text] [Related]
14. A double-blind controlled study of intramuscular zuclopenthixol acetate and liquid oral haloperidol in the treatment of schizophrenic patients with acute exacerbation.
Chouinard G; Safadi G; Beauclair L
J Clin Psychopharmacol; 1994 Dec; 14(6):377-84. PubMed ID: 7884017
[TBL] [Abstract][Full Text] [Related]
15. Haloperidol and reduced haloperidol concentrations in plasma and red blood cells from chronic schizophrenic patients.
Ko GN; Korpi ER; Kirch DG
J Clin Psychopharmacol; 1989 Jun; 9(3):186-90. PubMed ID: 2661607
[TBL] [Abstract][Full Text] [Related]
16. Haloperidol plasma level after a test dose as predictor for the clinical response to treatment in acute schizophrenic patients.
Louza Neto MR; Müller-Spahn F; Rüther E; Scherer J
Pharmacopsychiatry; 1988 Sep; 21(5):226-31. PubMed ID: 3227054
[TBL] [Abstract][Full Text] [Related]
17. The relationship of haloperidol concentrations to therapeutic response.
Perry PJ; Pfohl BM; Kelly MW
J Clin Psychopharmacol; 1988 Feb; 8(1):38-43. PubMed ID: 3350997
[TBL] [Abstract][Full Text] [Related]
18. Serum haloperidol concentrations and clinical response in acute psychosis.
Miller DD; Hershey LA; Duffy JP; Abernethy DR; Greenblatt DJ
J Clin Psychopharmacol; 1984 Dec; 4(6):305-10. PubMed ID: 6511996
[TBL] [Abstract][Full Text] [Related]
19. Effect of varying haloperidol plasma levels on negative symptoms in schizophrenia and schizoaffective disorder.
Volavka J; Cooper TB; Czobor P; Meisner M
Psychopharmacol Bull; 1996; 32(1):75-9. PubMed ID: 8927679
[TBL] [Abstract][Full Text] [Related]
20. An open study of risperidone liquid in the acute phase of schizophrenia.
Yoshimura R; Nakamura J; Shinkai K; Goto M; Yamada Y; Kaji K; Kakihara S; Ueda N; Kohara K; Ninomiya H; Egami H; Maeda H
Hum Psychopharmacol; 2005 Jun; 20(4):243-8. PubMed ID: 15830401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]